Imipenem (formerly N-formimidoyl thienamycin) and ceftazidime were investigated for their postantibiotic effect on Pseudomonas aeruginosa. Four strains of P. aeruginosa in the logarithmic phase of growth were exposed for 1 and 2 h to concentrations of antibiotics achievable in human serum. Recovery periods of test cultures were evaluated after dilution or addition of j-lactamase. A consistent postantibiotic effect against all strains was obtained with imipenem but not with ceftazidime. Although ceftazidime did not have a postantibiotic effect, it did suppress the growth of the organisms at concentrations equivalent to one-third of the MIC. The clinical implications of these effects need further evaluation.
Early studies demonstrated that staphylococci exposed to lethal concentrations of penicillin did not immediately resume growth after the drug was removed (11, 12) . Eagle and Musselman (5) later showed that this effect was not peculiar to staphylococci but could also be observed with other species.
More recent studies have characterized the postantibiotic effect (PAE) for gram-positive and gram-negative aerobic organisms (3, 4, 9, 15) . Of interest, inhibitors of protein and RNA syntheses have produced the longest PAE for most species (4). 13 -Lactam antibiotics produce a consistent PAE against gram-positive cocci when used at concentrations near the MIC, but none or a minimal effect was seen against gram-negative bacilli (3) . The duration of the PAE of ampicillin for Escherichia coli was less than 0.5 h despite exposing these organisms to concentrations 100 times their MIC (15) .
Pseudomonas aeruginosa, a significant pathogen for the cancer patient who is granulocytopenic, exhibited a PAE when exposed to gentamicin; but no or a negative PAE was demonstrated when the organism was exposed to ticarcillin, cefoperazone, or moxalactam (4) . McDonald and his colleagues have previously demonstrated a short PAE with imipenem against a single strain of P. aeruginosa (10 with antibiotic-free medium. The study was repeated for ceftazidime and imipenem. For this evaluation, however, the flasks were incubated with antibiotics for 2 h rather than 1 h and the antibiotics were removed by the addition of 2 ml of broad-spectrum Plactamase (Whatman Biochemicals, Ltd., Maidstone, Kent, England). To assure that the antibiotics were inactivated after the addition of P-lactamase, imipenem and ceftazidime concentrations were determined by high-pressure liquid chromatography and bioassay. A modification of the technique described by Bennett et al. (2) was used for the bioassay, with Bacillus subtilis as the indicator organism for imipenem and Morganella morganii as that for ceftazidime.
Bacterial counts of the flask contents were determined at (Table 3) . Ceftazidime produced no PAE against any of the strains tested. However, for ceftazidime a prolonged suppression of growth was observed against two of the strains when a 10-2 dilution of the culture was used, resulting in a final concentration of approximately one-third of the MIC. This suppressive effect was not seen when a i0-dilution was used (Fig. 1) . Amikacin produced 1-and 3.2-h PAEs against strains ATCC 27853 and 228, respectively. For the other two strains a PAE could not be determined because counts were <10 CFU/ml during the counting procedure.
Moxalactam produced a 0.5-h PAE against strain 13 but not against the remaining strains. These strains showed a more rapid rate of growth when compared with control cultures during the first hour after drug removal (negative PAE) (Fig. 2) .
Exposure for 2 h: drug inactivation by ,-lactamase, A PAE against all four strains of P. aeruginosa was observed after a 2-h exposure to imipenem (Table 4 ). Figure 3 (14) ; upon removal of these antibiotics, rapid septation probably occurs (up to 12 separate cells per filament) as shown with piperacillininduced E. coli filaments (7) . Thus there is a rapid (greater than log phase) increase in CFU, resulting in a "negative" PAE. Imipenem, like amdinocillin (formerly mecillinam), binds with great affinity to penicillin-binding protein 2, resulting in the formation of enlarged ovoid cells which rapidly lyse by a process that requires cyclic AMP (1) . Determination of damage to this particular enzymatic pathway by imipenem and how it may correlate with the presence of a PAE against P. aeruginosa requires more investigation.
The clinical significance of these effects has not been established. However, a PAE may be beneficial when dosing intervals are used such that concentrations of the drug at the site of infection become very low; yet, because of the PAE, the regrowth of the organisms would still be prevented.
On the other hand, those P-lactam antibiotics which do not induce a PAE would seem to require the continuous presence of the drug (by means of short dosing intervals or constant infusion) since regrowth occurs immediately after their concentration decreases below one-half to one-eighth of the MIC (13 In attempting to evaluate the importance of the PAE of imipenem in vivo, one may speculate that the presence of a PAE or the absence of a lag period before the onset of rapid kill may have contributed to the results observed by Johnson et al. (8) in a neutropenic rat model of pseudomonas bacteremia. In that study, imipenem resulted in improved outcome in comparison to moxalactam. Drugs were administered at 8-h intervals and serum concentrations were above the MBC for only 2 h. Imipenem provided effective therapy for the lethal P. aeruginosa infection, survival being significantly better than for moxalactam-treated animals. These results could not be attributed to higher or more prolonged serum levels of imipenem or to greater in vitro activity against the infecting pathogen.
Imipenem, with both a rapid onset of kill and an ability to produce a significant PAE against P. aeruginosa, can be considered to be unique at this time among the newer 13 
